Growth and dissemination of Lewis lung carcinoma in plasminogen- deficient mice

Blood

Volumn 90, Issue 11, 1997, Pages 4522-4531

  Bugge, Thomas H ^a   Kombrinck, Keith W ^a   Xiao, Qing ^a   Holmbäck, Kenn ^a   Daugherty, Cynthia C ^a   Witte, Dave P ^a   Degen, Jay L ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL SURVIVAL; COLLAGEN DEGRADATION; ENZYME INHIBITION; ENZYME SPECIFICITY; LEWIS CARCINOMA; LYMPH NODE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN ULCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, LEWIS LUNG; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030662107     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, cancer. Adv Cancer Res 44:139, 1985
2. Danø K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 9:189, 1994
3. Saksela O, Rifkin DB: Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 4:93, 1988
4. Vassali J-D, Wohlwend A, Belin D: The plasminogen activator/plasmin system. J Clin Invest 88:1067, 1991
5. Vassali J-D, Sappino A-P, Belin D: Urokinase-catalyzed plasminogen activation at the monocyte/macrophage surface: A localized and regulated proteolytic system. Curr Top Microbiol Immunol 181:65, 1992
6. Collen D, Lijnen HR: Fibrinolysis and the control of hemostasis, in Stamatoyannopoulos GS, Nienhuis AW, Majerus PW, Varmus H (eds): The Molecular Basis of Blood Diseases. Philadelphia, PA, Saunders, 1994, p 725
7. Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Danø K: Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 2:287, 1996
8. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJS, Degen JL: Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87:709, 1996
9. Werb Z, Mainardi C, Vater CA, Harris ED: Endogenous activation of latent collagenases by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 296:1017, 1977
10. Brunner G, Gabrilove J, Rifkin DB, Wilson EL: Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 6:1275, 1991
11. Odekon LE, Blasi F, Rifkin DB: Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 158:398, 1994
12. Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon cancer. Am J Pathol 138:1059, 1991
13. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K: The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51:4067, 1991
14. Pyke C, Graem N, Ralfkier W, Rønne E, Høyer-Hansen G, Brunner N, Danø K: The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53:1911, 1993
15. Skriver L, Larsson LI, Keilberg V, Nielsen LS, Andreassen PB: Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 99:752, 1984
16. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennely JJ, Andreassen PA: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827, 1990
17. Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Bontenbal M, Janicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101, 1992
18. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Danø, K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513, 1993
19. Ganesh S, Siene CEM, Heerding MM, Griffioen G, Lamers CBHW, Verspaget HW: Diagnostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54:4065, 1994
20. Mulcahy HE, Duffy MJ, Gibbons P, McCarthy P, Parfrey NA, O'Donoghue, DP, Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344:583, 1994
21. Oka T, Ishida T, Nishino T, Sugimachi K: Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenpcarcinoma. Cancer Res 51:3522, 1991
22. Pedersen H, Grøndahl-Hansen J, Francis D, Østerlind K, Hansen HH, Danø K, Brunner N: Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671, 1994
23. Heinert G, Kircheimer JC, Pfluger H, Binder H: Urokinase-type plasminogen activator as a marker for the formation of distant metastasis in prostate carcinomas. J Urol 140:1466, 1988
24. Heiss MM, Allgayer H, Gmetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: A reference to early systemic disease in solid tumors. Nat Med 1:1035, 1995
25. Nekarda H, Siewert JR, Schmitt M, Ulm K: Tumor-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343:117, 1994
26. Yu H, Schultz RM: Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50:7623, 1990
27. Kook YH, Adamski J, Zelent A, Ossowski L: The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13:3983, 1994
28. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611, 1983
29. Ossowski L: Plasminogen activator dependent pathways in dissemination of human tumors in the chick embryo. Cell 52:321, 1988
30. Ossowski L, Russo-Payne H, Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res 51:274, 1991
31. Hearing VJ, Law LW, Corti A, Apella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48:1270, 1988
32. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T: Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71:474, 1994
33. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T: Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 57:727, 1994
34. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90:5021, 1993
35. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87:4718, 1996
36. Min YM, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428, 1996
37. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor-2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92:205, 1995
38. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63:840, 1995
39. Bugge TH, Flick MJ, Daugherty CC, Degen JL: Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9:794, 1995
40. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circ Res 92:2585, 1995
41. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastasis by Lewis lung carcinoma. Cell 79:315, 1994
42. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbot BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:1, 1972
43. Holmbäck K, Danton MJS, Suh TT, Daugherty CC, Degen JL: Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO J 15:5760, 1996
44. Witte DP, Aronow BJ, Stauderman ML, Stuart WD, Clay MA, Gruppo RA, Jenkins SH, Harmony JA: Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol 143:763, 1993
45. Belin D, Vasalli J-D, Combepine C, Godeau F, Nagamine Y, Reich E, Kocher HP, Duvoisin RM: Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 148:225, 1985
46. Kristensen P, Eriksen J, Danø K: Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J Histochem Cytochem 39:341, 1991
47. Prendergast GC, Diamond LE, Dahl D, Cole MD: The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol 10:1265, 1990
48. Dvorak HF: Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650, 1986
49. Harris NL, Dvorak AM, Smith J, Dvorak HF: Fibrin deposits in Hodgkin's disease. Am J Pathol 108:119, 1982
50. Brown LF, Asch B, Harvey VS, Buchinski B, Dvorak HF: Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer Res 48:1920, 1988
51. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo K-T, Yeo T-K, Dvorak AM, Van De Water L, Siousat TM, Senger DR: Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 667:101, 1992
52. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF: Pathogenesis of ascites tumor growth: Fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 55:369, 1995
53. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM. Dvorak HF: Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55:376, 1995
54. Dvorak HF, Senger DR, Dvorak AM: Fibrin as a component of the tumor stroma: Origins and biological significance. Cancer Metastasis Rev 2:41, 1983
55. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145, 1992
56. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interaction with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541, 1993
57. Hayes DF: Tumor markers for breast cancer. Ann Oncol 4:807, 1993
58. Crawford HC, Matrisian LM: Tumor and stromal expression of matrix metalloproteases and their role in tumor progression. Invasion Metastasis 14:234, 1995
59. Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55:1856, 1995
60. Schwartz MK: Tissue cathepsins as tumor markers. Clin Chem Acta 237:67, 1995
61. Liotta LA, Steeg PS: Cancer metastasis and angiogenesis. Cell 64:327, 1991
62. Carmeliet P, Schoojans L, Kieckens L, Ream B, Degen JL, Bronson R, DeVos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419, 1994
63. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, von Figura K, Peters C: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 14:3599, 1995
64. Wilson CT, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM: Intestinal tumorgenesis is suppressed in mice lacking the metalloprotease matrilysin. Proc Natl Acad Sci USA 94:1402, 1997
65. Conway JG, Trexler SJ, Wakefield JA, Marron BE, Emerson DL, Bickett DM, Deaton DN, Garrison, D, Elder M, McElroy A, Willmott N, Dockerty AJ, McGeehan GM: Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis 14:115, 1996
66. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546, 1995
67. Albini A, D'Agostini F, Giunciuglio D, Paglieri I, Balanski R, DeFlora S: Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 61:121, 1995
68. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD: Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 93:3942, 1996
69. Anderson IC, Shipp MA, Docherty AJP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56:715, 1996